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A B S T R A C T
Reducing lipid accumulation in insulin target tissues is critical for the treatment of type 2 diabetes. This
study aimed to develop a biochemical assay in cells for high throughput (HTP) screening of anti-diabetic
drugs by reducing lipid accumulation via different mechanisms. We designed a new method to extract
triglyceride (TG) with KOH to allow biochemical quantification of TGs for HTP screening in 3T3-L1 cells.
This new method was validated for its biochemical properties with identical results of TG obtained with
or without KOH (r2 = 0.9978, p < 0.001) and a fourfold improvement in TG extraction recovery rate
(88–95%, p < 0.001) as compared to the conventional chloroform/methanol extraction (12–18%). The
ability of this phenotype screening to capture potential anti-diabetic drugs was verified by
pharmacological agents well known to alter lipid accumulation by different mechanisms including
AMPK activators, fatty acid synthesis inhibitors, PPARg activator and several lipogenic substrates. To
further demonstrate the application of this screening tool for discovery of new anti-diabetic drugs, we
screened >200 new candidates selected from Chinese medicine and identified 49 compounds from
different classes which reduced TG content by >50% at 1 mM or >75% at 10 mM. Finally, we tested two
selected leads (albiflorin and oxymatrine) in vivo and confirmed their efficacy in reducing visceral
adiposity, glucose intolerance and hepatic steatosis in high fat-fed or high fructose-fed mice. Our results
indicate that screening for the efficacy on lipid accumulation in cells by biochemical quantification of
TGs with KOH extraction is an effective tool for the identification of new anti-diabetic compounds.
 2012 Elsevier Inc. All rights reserved.
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/bio c hem p har m1. Introduction
The prevalence of type 2 diabetes (T2D) is increasing at an
alarming rate worldwide largely due to the increased prevalence of
obesity. It has been estimated that there are around 200 millionAbbreviations: Abs, absorbance; ACC, acetyl-CoA carboxylase; AF, albiflorin; AMPK,
AMP-activated protein kinase; ATG, arctigenin; BBR, berberine; BW, body weight;
CH-Con, standard chow; C/M, chloroform/methanol; DMEM, Dulbecco’s modified
Eagles’s medium; FA, fatty acid; FAS, fatty acid synthase; FBS, fetal bovine serum;
FXR, farnesoid  receptor; GTT, glucose tolerance test; HFD, high fat diet; HTP, high
throughput; IBMX, 3-isobutyl-1-methylxanthine; ip, intraperitoneal; KOH, potas-
sium hydroxide; LDH, lactate dehydrogenase; OA, oleanolic acid; OM, oxymatrine;
ORO, Oil Red O; PPAR, peroxisome proliferator-activating receptor; PSG, penicillin-
streptomycin-glutamine; RSG, rosiglitazone; SREBP-1c, sterol regulatory element-
binding protein-1c; STD, standard; T2D, Type 2 diabetes; TCM, traditional Chinese
medicine; TG, triglyceride; TOFA, 5-(tetradecyloxy)-2-furancarboxylic acid; TP,
triterpenoid; Veh, vehicle.
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http://dx.doi.org/10.1016/j.bcp.2012.07.003people suffering from T2D, and this figure is expected to increase to
over 320 million by 2030 [1]. It has been established that insulin
resistance (a reduced responsiveness of tissues, i.e. muscle and
liver, to insulin) is a major factor linking obesity (particularly
central adiposity) and T2D. At the pre-diabetic (insulin resistance
alone) stage, blood glucose is maintained relatively normal via a
compensatory increase in insulin secretion by the pancreas.
However, prolonged insulin resistance may eventually result in
beta-cell failure and the circulating insulin levels become
insufficient to control blood glucose, leading to overt hypergly-
caemia and the development of diabetes-associated complications.
Triglycerides (TGs) are commonly used as indicators of
intracellular accumulation of lipids. Although TGs do not directly
cause insulin resistance by themselves alone, they constitute the
major storage of lipid intermediates that can interrupt insulin
action by multiple mechanisms. For example, the intracellular
forms of fatty acids (FAs) and long-chain fatty acyl-CoAs can inhibit
hexokinase and glycogen synthase [2,3]; diacylglycerols can block
insulin signalling pathways by promoting protein kinase
C-dependent serine/threonine phosphorylation of IRS-1 [4];
furthermore, ceramide can dephosphorylate Akt and thus inhibit-
ing its activity [5]. The toxicity of these lipid metabolites can also
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to exacerbate insulin resistance at a later stage [6]. Therefore,
reducing ectopic lipid accumulation has been shown to reverse
insulin resistance and obesity.
The cellular level of TG is determined by de novo lipogenesis
(mainly by FA synthesis) and FA oxidation (mainly in mitochon-
dria). One of the most attractive mechanisms to promote a
reduction on intracellular lipid levels is the activation of AMP-
activated protein kinase (AMPK). This protein phosphorylates and
inhibits the activity of acetyl-CoA carboxylase (ACC). ACC mediates
the first step in the de novo synthesis of fatty acids and
simultaneously, its product malonyl-CoA blocks the entry of FAs
in the mitochondria for oxidation by inhibiting the carnitine
palmitoyltransferase shuttle system. Thus, AMPK has been an
attractive target for the discovery of drugs with potential efficacy
for T2D and obesity [7]. The other mechanism to reduce cellular TG
level is the inhibition of FA synthesis, particularly in adipose tissue
and liver, because these tissues exhibit elevated de novo
lipogenesis capacity that can exacerbate lipid accumulation.
Indeed, a number of compounds acting at key steps of the
lipogenic pathway have been shown to reduce obesity, hepatic
steatosis and/or insulin resistance, such as specific inhibitors of
fatty acid synthase, C75 and cerulenin [8], ACC inhibitor
5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) [9] or sterol
regulatory element-binding protein-1c (SREBP-1c) [10].
Here, we established a HTP phenotypic screening assay with a
cellular TG level as a measurement capable of capturing the lipid-
lowering efficacy from actions at different sites in lipid metabolic
pathways. This newly developed screening assay was made
possible by using KOH based on its ability to lyse cells and
hydrolyse TGs [11] to overcome the obstacles encountered with
the conventional organic solvent. Following the validation by a
series biochemical and pharmacological tests, we used this HTP
assay to screen more than 200 candidates selected from different
classes of compounds from traditional Chinese medicine (TCM).
Our results identified over 40 potential anti-diabetic compounds
and among them we confirmed the efficacy of newly identified
compounds albiflorin in high fat-fed mice and oxymatrine in high
fructose-fed mice. These findings provide strong support for the
application of this screening assay for the discovery of novel anti-
obese and anti-diabetic drugs.
2. Materials and methods
2.1. Regents, chemicals and test compounds
Insulin, dexamethasone, DMSO, biotin, 3-isobutylxanthine
(IBMX), AICAR, berberine (BBR), oleanolic acid (OA), arctigenin
(ATG), betulin, C75, cerulenin, 5-(tetradecyloxy)-2-furancar-
boxylic acid (TOFA), rosiglitazone (RSG), fructose, genipin
(98.0%), bile acids including cholic acid, deoxycholic acid and
chenodeoxycholic acid, as well as chemicals and solvents used in
various buffers were purchased from Sigma–Aldrich (Melbourne,
Australia). Tissue culture reagents were obtained from Invitrogen
(Melbourne, Australia). The compounds tested were kindly
supplied via or by Dr Lihong Hu and Dr Yang Ye of the Shanghai
Institute of Materia Medica, Chinese Academy of Sciences
(Shanghai, China) and Dr Jun Xu of the School of Pharmaceutical
Sciences, Sun Yat-sen University (Guangzhou, China). Specifically,
albiflorin (98.0%) was obtained from Baoding Yunxin Trade (Hebei,
China) and oxymatrine (98.0%) from Hangzhou Tianlong Biotech-
nology (Hangzhou, China). Tiliroside (>98.0%) was obtained from
Meryer Chemical Technology (Shanghai, China). The derivatives of
albiflorin, oxymatrine, berberine, genipins and tiliroside were
developed at Shanghai Institute of Materia Medica by modifying
their chemical structures. Triterpenoids were obtained from thepurification of the extracts of bitter melon as we recently described
[12]. FXR ligands and other bile acid analogues were developed in
Sun Yat-sen University. Other test compounds were obtained from
the chemical library of Sun Yat-sen University after computer-
based virtue screening against the targets for lipid metabolism
[13]. To improve the likelihood of success and minimize the
numbers for screening, we selected the candidates with a wide
range of chemical diversity by one of the two following virtual
screening processes [12–14], The first virtual screening was based
on careful evaluation of documented (or reported) effects
implicated for diabetes or related conditions as used in our recent
identification of BBR and its derivatives from Golden Seal [14] and
cucurbitane triterpenoids from Bitter Melon [12]. The second
process involved computer modelling possible binding of test
compounds to cellular targets, such as the farnesoid X receptor
(FXR) (a regulator of lipid metabolism [15]), in the software
available to us by the similar approach as described for the liver X
receptor [13].
2.2. Cell culture
3T3-L1 mouse embryonic fibroblasts (American Type Culture
Collection, Manassas, VA) were cultured in Dulbecco’s modified
Eagles’s medium (DMEM) supplemented with 10% (v/v) foetal
bovine serum (FBS) and 1% (v/v) penicillin-streptomycin-gluta-
mine (PSG) at 37 8C in 5% CO2. The 3T3-L1 pre-adipocytes were
seeded into 48- or 96-well micro-plates and allowed to reach full
confluence. To induce pre-adipocyte differentiation, 2-day post-
confluent cells were incubated in differentiation medium (DMEM
containing 10% FBS, 1% PSG, 2 mg/ml insulin, 100 ng/ml dexa-
methasone, 500 mM IBMX and 10 ng/ml biotin) for 3 days before
switching to post-differentiation medium (DMEM with 10% FBS,
1% PSG and 2 mg/ml insulin) for additional 3 days. To assess their
effects on lipid accumulation, the test compounds were dissolved
in DMSO and supplemented at the concentrations indicated in the
figure legends throughout the course of the differentiation. Test
compounds were made as stocking solutions and stored at 20 8C
in aliquots. They were added on day 0 in differentiation medium
(for 3 days) and replaced with another aliquot in post-differentia-
tion medium on day 3 (for another 3 days). 3T3-L1 cells cultured in
DMEM supplemented with 0.1% DMSO were used as a vehicle
control for all experiments. Cells were monitored and photo-
graphed using the Nikon TS100F inverted microscope and camera
(Nikon Instruments Inc., USA).
2.3. Design for a novel technique of TG extraction for biochemical
assay
At the end of the 3-day post-differentiation medium incubation,
the culture medium was removed and the cells were washed twice
with ice-cold PBS buffer (0.2 M NaCl, 10 mM Na2HPO4, 3 mM KCl,
2 mM KH2PO4, pH 7.4), before subjected to drying in a 37 8C
incubator (Ratek Instruments, Australia). Cells were lysed and TGs
were extracted by the addition of KOH (final concentration 50 mM)
followed by incubation at 60 8C for 10 min and centirfuged at
4000 rpm for 5 min. For the conventional extraction method [16],
cells were scraped immediately following the addition of the
chloroform/methanol (2:1) solution. The cell lysate was mixed
with 0.6% NaCl solution and centrifuged at 2000 rpm for 10 min.
The bottom organic layer containing the TG was collected and
dried under nitrogen gas at 45 8C. TG was reconstituted in ethanol
for the measurement using a commercial Peridochrom TG GPO-
PAP kit (Roche Diagnostics, Castle Hill, New South Wales,
Australia) following the manufacturer’s instructions in a spectro-
photometer. To evaluate the influence of KOH on the enzymatic
assay, the TG kit was tested in the presence of 50 mM KOH (used
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Aldrich, Melbourne, Australia) as a TG donor [3,4]. The recovery
rate of TG extraction from 3T3-L1 cells was assessed by adding
known amounts of TGs from the intralipid before the extraction
either by KOH or the C/M mixture.
2.4. Oil red O (ORO) staining
Oil red O (ORO) staining was used in combination with light
microscopy to assess pre-adipocyte differentiation as previously
described [17]. Briefly, the treated differentiated 3T3-L1 cells were
washed twice with ice-cold PBS buffer and fixed in 10% neutral
formalin overnight before staining with a 0.35% (w/v) ORO solution
in isopropanol for 10 min. Excess stains were then removed by
rinsing the cells under water and then dried before microscopic
examination. For quantitative analysis, ORO was eluted with
isopropanol and the absorbance was measured at 485 nm in a
spectrophotometer.
2.5. Determination of lactate dehydrogenase (LDH) release
After cells were treated with compounds for 6 days, the
medium and lysate were collected to measure the activity of
lactate dehydrogenase (LDH) released into the culture medium
from cells. The medium was collected and centrifuged at 1000 rpm
at 4 8C for 10 min to remove detached cells. To measure the
intracellular LDH activity, 3T3-L1 cells were lysed by two freeze-
thaw cycles (chilling the plate at 80 8C for approximately 30 min
followed by thawing at 37 8C for 15 min) after wash with ice-cold
PBS buffer. The cell lysate was then centrifuged at 1000 rpm for
4 min, and the supernatant was stored at 4 8C until ready to use.
The enzyme activity in the whole cell lysate and medium was
determined by the CytoTox 961 Non-Radioactive Cytotoxicity
Assay kit (Promega, Melbourne, Australia) according to the
manufacturer’s protocol. Briefly, 50 ml of the diluted medium
(1:5) or cell lysate (1:10) were transferred onto a plate followed by
addition of the reconstituted substrate mixture. The absorbance of
the samples was read at 490 nm using the Polarstar Optima
microplate reader (BMG Labtech, Germany). LDH released into the
medium was expressed as a percentage of the total LDH activity
(ratio of LDH in lysate and in the medium) as described.
2.6. Animal studies
Male C57BL/6J mice (10 weeks old) were purchased from the
Animal Resources Centre (Perth, Australia). The animals were kept
in a temperature-controlled room (22  1 8C) on a 12-h light/dark
cycle with free access to food and water. Animals were randomly
assigned to receive a high fat (60%) diet (HFD) ad libitum to generate
insulin resistance [12,14] or a high fructose (35% fructose and 35%
starch) diet (HFru) to generate hepatic steatosis [18]. Animals were3T3-L1  
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Fig. 1. Design of KOH extraction for biochemical assay of TG content in 3T3-L1 cells
quantification of cell triglyceride (TG) content. Multiple procedures involved in the ORO m
the conventional extraction with chloroform/methanol (C/M). Multiple steps involved i
(C) Designed method for TG extraction and cell lysis with KOH. This new method intende
biochemical assay of TG for HTP drug screening.fed for 8 weeks with or without albiflorin (AF, 100 mg/(kg day) in
HFD), for the final 2 weeks. In a separate study, HFru-fed mice received
oxymatrine (OM, 100 mg/(kg day) in diet, 1 week) after 3-day HFru-
feeding (unless indicated otherwise). Body weight, food intake and
fasting blood glucose level were monitored on weekly basis. After two
weeks of AF treatment in HFD mice, glucose tolerance test (glucose load
2 g/kg BW, i.p.) was performed after 6-h fasting. Glucose level of blood
collected from the tail vein was measured at designed time points using
the Accu-Chek glucometer (Roche Diagnostics, Castle Hill, New South
Wales, Australia). The effect of OM on glucose tolerance in HFru-fed
mice was assessed after 2 weeks of treatment at a glucose load of 3 g/kg
(i.p.) based on our previous studies [18]. All animal experiments were
approved by the Animal Ethics Committee of RMIT University
(Approval No #1012) following the guidelines issued by the National
Health and Medical Research Council of Australia.
2.7. Statistical analyses
Data were presented as means  SE. Unpaired student test was
performed for comparison of relevant groups. Pearson’s two-sided
correlation was used for correlation calculation. Differences at
p < 0.05 were considered to be statistically significant.
3. Results
3.1. Validation of the novel TG extraction method for HTP biochemical
assay
The conventional method for the extraction of TGs from tissues
with organic solvents requires a series of steps including the
separation of organic and aqueous phases [16]. Thus we designed a
one-step method to extract TG with the use of KOH based on its
ability to lyse cells and hydrolyse TGs [11] (Fig. 1). We first tested
whether or not KOH may influence the biochemical assay. Fig. 2A
shows that at the concentration (50 mM) designed for TG
extraction KOH did not have any significant influence on the
biochemical assay for the quantification of TG. The obtained results
in the presence of KOH were almost identical to those obtained in
the absence of KOH as indicated by a high degree of linear
correlation (Y = 1.1416X, r2 = 0.9978, p < 0.001). We next exam-
ined if KOH could extract a similar amount of TGs from cells, by
adding 1.0 or 2.5 mg TG (50–100% of TG from 3T3-L1 adipocytes) to
a cell culture plate. As shown in Fig. 2B, the recovery rates of TGs
extracted with KOH at these two concentrations of added TG were
87.8  4.6% and 95.1  0.5%, respectively. These recovery rates were
approximately four times of those extracted by C/M (12.1  8.9 and
18.0%  8.4%, respectively, p < 0.001). Furthermore, the obtained
values of TGs extracted with KOH were quantitative in proportion to
amount added (0.88  0.05 mg from 1.0 mg and 2.4  0.01 mg from
2.5 mg) (Fig. 2C). Extra ct  
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Fig. 2. Validation of the KOH extraction method for biochemical measurement of TG. (A) Influence of KOH in cell-free biochemical assay per se. Various concentrations of TG from
Intralipid were measured with an enzyme-based TG kit under cell-free conditions in the presence or absence of KOH (50 mM). (B and C) Extraction of TG from 3T3-L1 cells using
KOH as compared with the chloroform/methanol (C/M) solvent. 3T3-L1 cells were seeded into a 12 well-plate and cultured in DMEM containing 10% FBS and 1% PSG. Two days
after the confluence, cell medium was removed and washed twice with ice-cold PBS. TG was extracted using KOH (50 mM) or C/M (2:1) mixture. The recovery rate of TG extraction
was calculated from values obtained with or without added TG (1.0 or 2.5 mg from Intralipid). Data are means  SE from three independent experiments. yyp < 0.01.
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pharmacologic agents
In order to verify the ability of this new assay as an end-point
measurement to capture the effect on lipid accumulation inducedFig. 3. Validation of the TG assay as an endpoint screening for drugs acting at
different sites of lipid metabolism. (A) Assessment of the ability of the new
screening assay to detect intracellular lipid accumulation. 3T3-L1 cells were seeded
into a 48 well-plate and cultured in DMEM. Two days after confluence, cells were
incubated with differentiation medium (DMEM containing 10% FBS, 1% PSG, 2 mg/
ml insulin, 100 ng/ml dexamethasone, 500 mM IBMX and 10 ng/ml biotin) for 3
days. Differentiated cells were cultured for additional 3 days in DMEM with 2 mg/ml
insulin (post-differentiation medium) with modulators affecting lipogenesis and/or
lipolysis. (B) Lactate dehydrogenase (LDH) release. The cell medium and lysate were
collected 6 days after the incubation with the modulators. LDH release was
determined by its activity in the medium relative to the cell lysate and corrected
with the vehicle (Veh) control. These lipogenesis/lipolysis modulators included (i)
AMPK activators – AICAR (AIC, 500 mM), berberine (BBR), oleanolic acid (OA) and
arctigenin (ATG); (ii) lipogenic inhibitors – betulin (SREBP-1c inhibitor), C75 (FAS
inhibitor), cerulenin (Ceru, FAS inhibitor), TOFA (ACC inhibitor); and (iii) lipogenic
enhancers – rosiglitazone (RSG, PPARg agonist) and fructose (Fru, 20 mM). Data are
means  SE from three independent experiments. yyp < 0.01 vs Veh.by different upstream mechanisms, we tested a number of
pharmacological agents well known to promote FA oxidation,
inhibit or enhance lipogenesis in our newly developed assay
system. As expected, the AMPK activators AICAR [19], BBR [14],
oleanolic acid (OA) [12], arctigenin (ATG) [20] all reduced the TG
levels significantly (p < 0.01) at 1 and/or 10 mM (Fig. 3A). Detailed
examination revealed a dose-depend efficacy for these agentsFig. 4. Comparison of results obtained from the method of ORO staining. 3T3-L1
cells were cultured and incubated under the same conditions as described in the
legend of Fig. 3. At the end of the experiment, cells were stained with ORO for the
quantification of TG content. (A) Quantified results by measuring the optical density
of ORO stained cells after the incubation with lipogenesis/lipolysis modulators. (B)
Correlation of the results from the new assay using the new KOH-enzyme method
vs the ORO staining. Data are means  SE from three independent experiments.
yyp < 0.01 vs Veh.
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C75 and cerulenin (specific FAS inhibitors [9]), betulin (specific
SREBP-1c inhibitor [10]), and tetradecyloxyfuroic acid (TOFA,
specific ACC inhibitor [9]) (all p < 0.05, Fig. 3A). In contrast,
incubation with 20 mM fructose (Fru, lipogenic substrate [21]) or
1–10 mM rosiglitazone (RSG, specific PPARg agonist [22]) in-
creased TG accumulation by more than 150% (p < 0.05 for both).
To exclude a possibility of the decrease in TG content resulting
from cytotoxicity, we determined the LDH activity in the cultured
media as an indicator of cell damage. Fig. 3B shows that apart from
the higher concentration (10 mM) of BBR and betulin which
moderately elevated the LDH activity to the similar levels of Fru
and RSG, there was no significant increase in LDH activity for other
test agents at the concentrations which reduced TG content.
Consistent with the results of LDH, the cells displayed a healthy
morphology in response to these treatments (Fig. S2).
3.3. Comparison with results obtained from ORO staining
As ORO staining is widely used to screen the changes in lipid
content in cultured cells [17], we compared the values of
intracellular lipid content obtained from new method with the
semi-quantitative ORO method. As shown in Fig. 4A, the ORO
staining method confirmed all the responses we detected using our
new screening assay. The obtained values of TG were all
significantly reduced by lipogenesis inhibitors BBR, betulin, C75,
cerulenin and TOFA (> 40%) but increased by Fru and RSG (>130%)
under the experimental conditions (all p < 0.01). The mean values
of results obtained from these two assays were significantly
correlated (Y = 1.0906X, r2 = 0.9032, p < 0.001) (Fig. 4B).Fig. 5. Application of the new HTP screening for identification of anti-diabetic compound
developed HTP screening in 96-well plates for the identification of anti-diabetic leads by
selection of promising compounds (leads) for further studies in vivo. (B) Overview of the n
as a compound with the efficacy in lowering TG for >50% at 1 mM or >75% at 10 mM.3.4. Screening of test compounds for their effects on TG accumulation
in 3T3-L1 adipocytes
Following the biochemical and pharmacological validations as
described above, we applied this new screening protocol in 48-well
plates (as illustrated in Fig. 5A) in an attempt to identify potential
lipid-lowering drugs by targeting the compounds developed from
traditional Chinese medicine (TCM). Among the 207 candidates
selected for the screening, we detected 49 hits (compounds with
efficacy in reducing TG accumulation by >50% at 1 mM or >75% at
10 mM) (Fig. 5B). These identified hits included several classes of
compounds with different core structures, particularly derivatives
of BBR (Fig. 6A), triterpenoids (TP, Fig. 6B), tiliroside (Fig. 6C),
oxymatrine (Fig. 6D), albiflorin (Fig. 6E) and ligands for farnesoid X
receptor (FXR, Fig. 6F).
3.5. Demonstration of therapeutic effects in vivo of leads selected
from the identified hits
We next tested if our new screening system may guide the
identification of new leads with anti-diabetic and/or anti-steatotic
efficacy in vivo by confirming the therapeutic effect of the elected
candidates in a well-recognized model of insulin resistance and
obesity (HFD), and hepatic steatosis (HFru), respectively. Based on
the screening results (illustrated in Fig. 5), we elected to examine
albiflorin (AF, an analogue of paeoniflorin). AF has been suggested
to be a key ingredient of Paeonia radix which has been shown to
exert acute effect in reducing blood glucose in diabetic mice [23].
As shown in Table 1, HFD mice with oral administration of AF at
100 mg/(kg day) (based on the reported i.p. dose of 30 mg/kg useds from TCM. (A) Schematic diagram for the drug discovery process using the newly
 targeting TCM. It also illustrates the consideration of additional information for the
umbers of compounds identified (namely hits) from different classes. A hit is defined
 Results were obtained from three independent experiments.
Fig. 6. Representative classes of compounds identified from the new HTP screening. 3T3-L1 cells were differentiated and treated with test compounds at 1 and or 10 mM.
berberine (BBR, 1 mM) or rosiglitazone (RSG, 1 mM) were used as the standard (STD) positive and negative controls. (A) BBR derivatives, (B) tetracyclic and pentacyclic
triterpenoids (TP), (C) tiliroside and its derivatives, (D) oxymatrine and its derivatives, (E) albiflorin and its analogues (AFs) and (F) farnesoid X receptor (FXR) ligands with the
core structure for each class. Data are means  SE from one independent experiment and for each of experiment triplicates were performed.
Table 2
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weight (by 45%, p < 0.01) and visceral adiposity (indicated by a 68%
reduction in epididymal fat mass, p < 0.01) compared with control
HFD mice. These effects occurred in the absence of any influence on
caloric intake (p > 0.05). Consistent with the efficacy on obesity, AF
treatment significantly improved glucose tolerance, as indicated
by 43% reduction (p < 0.01) in the area under the curve (iAUC) forTable 1
Metabolic effects of the identified lead albiflorin in insulin resistant mice induced
by chronic high fat feeding.
CH-Con HFD-Con HFD-AF
Body weight prior treatment (g) 26.4  0.5 27.6  0.6 27.0  0.4
Body weight after treatment (g) 27.2  0.5 28.8  0.8* 27.5  0.4
Body weight gain (g) 0.81  0.08 1.20  0.17* 0.66  0.14yy
Caloric intake (kcal/(mouse day)) 10.6  0.5 10.2  0.2 11.4  0.7
Epididymal fat mass (% BW) 1.24  0.12 3.32  0.25** 1.06  0.08yy
Blood glucose (mM) 9.4  0.3 10.8  0.3 11.8  0.3
ipGTT iAUC (mM  90 min) 740  70 1270  83** 722  64yy
Body weight gain, daily food intake, fasting glucose, and epididymal fat pad weights
for C57BL/6J mice fed 8 weeks on either standard chow (CH-Con), high fat diet
(HFD-Con), or HFD supplemented with albiflorin (AF, 100 mg/(kg day) for 2 weeks)
(HFD-AF). Glucose tolerance test was conducted with an intraperitoneal injection
(ipGTT) of glucose load of 2 g/kg. iAUC, incremental area under the curve of blood
glucose during the ipGTT. Data represents the mean  SE of 7–10 mice for each group.
* p < 0.05 vs CH-Con.
** p < 0.01 vs CH-Con.
yy p < 0.01 vs HFD-Con.blood glucose during the ipGTT. To further test the application of
new screening system, we examined the effect of oxymatrine (OM)
because this alkaloid (rich in Sophora flavescens) has been used in
humans as a safe oral drug in treatment of hepatic fibrosis [24]. As
shown in Table 2, oral administration of OM for one week was ableMetabolic effects of the identified lead oxymatrine on hepatic steatosis induced by
high fructose feeding.
CH-Con HFru-Con HFru-OM
Body weight prior treatment (g) 25.8  0.6 25.8  0.7 25.3  0.6
Body weight after treatment (g) 26.3  0.6 26.4  0.6 25.2  0.6
Body weight gain (g) 0.5  0.2 0.6  0.1 0.0  0.1*,y
Caloric intake (kcal/(mouse day)) 11.3  1.1 14.3  0.6 14.4  1.2
Epididymal fat mass (% BW) 1.1  0.0 1.7  0.1** 1.5  0.1**
Liver triglyceride (mmol/g) 11.6  1.4 23.9  2.5** 13.5  1.2yy
Blood glucose (mM) 9.8  0.3 11.7  0.6* 9.8  0.6
ipGTTa iAUC (mM  90 min) 981  90 1256  60* 1050  92y
Body weight gain, daily food intake, epididymal fat pad weights and liver
triglyceride content for C57BL/6J mice fed 1 week on either standard chow (CH-
Con), high fructose diet (HFru-Con), or HFru supplemented with oxymatrine (OM,
100 mg/(kg day)) (HFru-OM).
a ipGTT was performed after two weeks of oral administration of OM at a glucose
load of 3 g/kg BW. Data represents the mean  SE of 7–13 mice for each group.
* p < 0.05 vs CH-Con.
** p < 0.01 vs CH-Con.
y p < 0.05 vs HFru-Con.
yy p < 0.01 vs HFru-Con.
Fig. 7. Illustration of the screening on lipid accumulation for identification of anti-
diabetic and anti-obese drugs. As excess lipid accumulation is a major cause of
insulin resistance in T2D and obesity, drugs that eliminate excess lipid
accumulation (in liver and muscle) can improve glucose homeostasis by
reversing lipid-induced insulin resistance. Similarly, reducing lipid accumulation
in fat tissue can alleviate obesity. The present study has established a HTP assay in
cells to determine TG accumulation as a phenotypic screening tool for the
identification of new anti-diabetic and anti-obese drugs. This screening assay is
capable of capturing drugs that act at various cellular targets in the upstream
pathways of lipid metabolism which either increase FA oxidation (energy
expenditure) or inhibit de novo lipogenesis.
X.-Y. Zeng et al. / Biochemical Pharmacology 84 (2012) 830–837836to reduce body weight gain (p < 0.05) and eliminating hepatic
steatosis (p < 0.05) in HFru fed mice, a model of fatty liver due
induced by de novo lipogenesis [18]. After 2 weeks of administra-
tion of OM, glucose tolerance was significantly improved (iAUC:
1050  92 vs 1260  60 mM  90 min, p < 0.05, n = 8/group).
4. Discussion
As excess accumulation of lipids in cells is a hallmark of obesity
and insulin resistance [25], elimination of elevated cellular lipid
levels is an effective approach for the treatment of these
pathological conditions [2–4]. Based on this concept, we estab-
lished a biochemical assay of TGs in cells as an HTP screening tool
by designing a new lipid extraction method in order to identify
compounds with potential efficacy for obesity and associated
metabolic diseases. With this newly developed screening tool, we
screened 207 compounds selected from two TCM banks based on
extensive evaluation of TCM database [12,14] and/or computer
modelling [13,26]. Among them, 49 showed an efficacy in reducing
TG by >50% at 1 mM or >75% at 10 mM, which we regarded as
identified hits. Based on their drug-like properties and sufficient
quantity available to us, we demonstrated the in vivo anti-diabetic
and anti-steatotic effects of two novel leads (AF and OM) identified
from these hits. Our results provide the proof of concept for the use
of this HTP biochemical screening tool for the discovery of novel
anti-diabetic drugs.
Up till now, the ORO staining has been commonly used in
adipocytes to screen the efficacy on lipid content [17], particular
for drugs promoting cell differentiation such as PPARg agonists
[22]. However, this method involves multiple processes which are
time consuming and can be labour intensive when used at a large
scale. Furthermore, there is concern about the specificity and
the inaccuracy of the results obtained from the ORO staining [17].
Therefore, it would be advantageous to develop an HTP screening
for the cell TG levels based on a biochemical assay of TG widely
used for in plasma and tissue samples. To overcome the technical
obstacles in applying the biochemical assay for HTP screening, we
designed a method of TG extraction using KOH based on its ability
to lyse cells and hydrolyse TGs [11]. This new method provides
advantages over the organic extraction that requires multiple
steps, allowing the biochemical assay performed in a micro-plate
for HTP drug screening. Importantly, KOH extraction produced an
almost full recovery of TG (88–95%), which is far more superior to
the 12–18% of recovery obtained by the C/M method. Our new
procedure also substantially improves the efficiency of whole TG
assay (approximately 2 h) compared to the ORO staining and the C/
M extraction method, which usually require much longer time.
Cellular TG level can be regulated by either the lipogenic and FA
oxidative pathways. The HTP assay established with the new
extract method was able to capture the expected effects of well-
defined pharmacological agents in lipid metabolism. Among them,
AICAR, BBR, bitter melon triterpenoid and ATG have been
demonstrated to activate AMPK in previous studies including
ours [12,14,19,20]. Activated AMPK can reduce cellular lipid
accumulation by promoting FA oxidation [27] and inhibiting
lipogenesis [28]. Decreased TG was also evident, as predicted, in
the presence of lipogenic inhibitors acting at the site of SREBP-1c
(betulin, [10]), ACC (TOFA [9]) or FAS (C75 and cerulenin [9]).
Furthermore, our results also showed that our screening system
was sensitive in detecting increased TG accumulation in response
to lipogenic substrates (indicated by fructose [21]) and PPARg
agonists (indicated by RSG [22]). These results verify the suitability
of this HTP screening to capture potential anti-diabetic drugs
which alter lipid metabolisms by acting at different cellular sites.
Recently, we identified two anti-diabetic compounds such as
BBR and cucurbitane triterpenoids from the plants used in TCM forthe treatment of diabetes and related conditions [12,14].
Compared with a random screening of natural products, TCM
has been a much more fruitful resource as it enables us to perform
careful prior analysis [12,14], as well as computation [13] to reduce
the large numbers of compounds to a handful of highly selected
candidates for biological screening. Using this approach, we
selected 207 candidates representing a wide range of chemical
diversity (for new discovery) or different structures of the same
class of compounds (e.g. BBR derivatives) for the screening of novel
anti-diabetic drugs using the method established in this study.
Apart from obtaining detailed information for the new derivatives
from BBR and TP which would allow for detailed structure–activity
analysis, our results also confirmed a number of compounds which
have been suggested to affect lipid metabolism including tiliroside
[29], oxymatrine [30] and FXR ligands [13]. Collectively, these data
demonstrate that the screening of the efficacy on cellular lipid
accumulation is an effective tool to identify novel compounds with
anti-diabetic properties.
Based on the screening data along with the analysis for their
drug-like properties, we selected AF and OM for further studies in a
model of insulin resistant induced by chronic high fat feeding and
hepatic steatosis induced by high fructose feeding, respectively. AF
is an active ingredient found in herbal remedies (e.g. Paeonia radix)
with a good oral absorption property and pharmacokinetics in vivo
[31]. AF is widely used in TCM for its antibiotic, anti-inflammatory
and anti-allergic properties with little adverse effects [32,33]. In
addition, AF has been reported to lower blood glucose in
hyperglycaemic mouse models without increasing pancreatic
insulin secretion [34]. We found that AF was able to attenuate
the increased body weight gain, visceral adiposity and glucose
intolerance induced by chronic high fat feeding without significant
effects on food intake, indicating its therapeutic potential for
treatment of obesity and diabetes. We further tested the potential
X.-Y. Zeng et al. / Biochemical Pharmacology 84 (2012) 830–837 837application of our screening system by examining another
identified lead OM in HFru-fed mice and confirmed its efficacy
in reducing body weight gain, hepatosteatosis and glucose
intolerance. This may contribute to its reported efficacy for liver
fibrosis [35] because hepatosteatosis is an early event of
steatohepatitis [36] which could result in liver fibrosis. Taken
together, our in vivo data further support the use of the method
established in the present study for the identification of new anti-
diabetic, -obesity and -hepatosteatotic drugs.
In summary, the present study established a new assay to
determine TG accumulation in 3T3-L1 cells as a reliable phenotypic
screening tool capable of identifying new drugs with anti-obese
and anti-diabetic properties by reducing lipid accumulation via
different mechanisms. As illustrated in Fig. 7, our results provide
the proof of concept for the use of this approach which could be
extended to other cell types (such as HepG2 hepatocytes or L6
myocytes) to examine the effect on cell-specific lipid metabolism
and serve as a base for further investigation of the effect on FA
oxidation, uptake, synthesis and transport.
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